演題詳細

ポスター / Poster

ポスター 32 (Poster 32) :悪性リンパ腫:治療

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
磯部 泰司 (Yasushi Isobe):1
1:聖マリアンナ医科大学 血液・腫瘍内科
 
前へ戻る

A pilot study of dose-adjusted THP-EPOC (DA-THP-EPOC) therapy in patients with newly diagnosed PTCL

演題番号 : PS-1-243

松原 えり奈 (Erina Matsubara):1、原田 靖彦 (Yasuhiko Harada):1、青木 智広 (Tomohiro Aoki):1、森下 喬允 (Takanobu Morishita):1、鈴木 達也 (Tatsuya Suzuki):1、内田 俊樹 (Toshiki Uchida):1、小椋 美知則 (Michinori Ogura):1

1:Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital

 

Background: A standard of care in peripheral T-cell lymphoma (PTCL) has been still CHOP, although most of patients (pts) with PTCL eventually relapse after CHOP. Since pirarubicin (THP) was reported to be more effective in PTCL than doxorubicin, we conducted a pilot study of dose-adjusted (DA) THP-EPOC therapy in newly diagnosed PTCL.
Patients and Methods: Pts with newly diagnosed PTCL were eligible. DA-THP-EPOC regimen {THP (Day1-4), VP-16 (Day1-4), VCR (Day1-4), CPA (Day5) and PSL (Day1-5)} was delivered every 3 weeks. Doses (dose-level) were adjusted based on the rule of original DA-EPOCH. Results: A total of 5 pts (4 PTCL-NOS and 1 AITL, 4 stage III and 1 stage IV) with a median age of 76 (range 27-77) years were enrolled. Two pts completed 6 cycles with increase of dose-level (level 2 and 3). In one pt with performance status (PS) 3, DA-THP-EPOC was discontinued after 1 cycle due to grade (G) 3 cognitive disturbances. One pt with PS 4 died of febrile neutropenia after 1 cycle. In one pt, after 2 cycles, salvage chemotherapy was delivered because of insufficient efficacy (SD). G4 hematological toxicities included neutropenia (5/5), thrombocytopenia (3/5), anemia (1/5) and febrile neutropenia (1/5). G3/4 non-hematological toxicity was not observed except G3 cognitive disturbance in one pt. The overall response rate (ORR) was 80% (2 CR, 2 PR and 1 SD).
Conclusion: DA-THP-EPOC therapy was effective especially if 6 cycles were delivered and well tolerated in pts with good PS. Further study in pts with good PS to evaluate the efficacy and safety is warranted.

前へ戻る